CGEM
Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$22.09
−0.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | 306.0K | — | — |
| Gross Profit | — | — | (306.0K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 171.5M | 187.4M | 142.9M | 148.2M | 91.9M |
| SG&A Expense | 50.3M | 54.2M | 53.7M | 42.5M | 40.2M |
| General & Admin Expense | 50.3M | 54.2M | 52.8M | 42.5M | 40.2M |
| Selling & Marketing Expense | — | — | 894.0K | — | — |
| Other Expenses | — | — | — | 440.0K | (276.8M) |
| Total Operating Expenses | 221.8M | 241.6M | 196.6M | 191.1M | (144.6M) |
| Cost and Expenses | 221.8M | 241.6M | 196.9M | 191.1M | (144.6M) |
| Operating Income (EBIT) | (221.8M) | (241.6M) | (196.9M) | (191.1M) | 144.6M |
| Non-Operating | |||||
| Interest Income | 17.5M | 22.2M | 29.7M | 21.6M | 6.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 17.5M | 22.2M | 29.7M | 21.6M | 6.6M |
| Other Non-Op Income/Expense | 17.1M | 21.8M | 29.5M | 21.9M | 6.7M |
| Non-Operating Income (excl Interest) | (13.1M) | (21.8M) | (29.5M) | (440.0K) | 276.8M |
| EBT (Pre-Tax Income) | (204.7M) | (219.9M) | (167.5M) | (169.2M) | 151.3M |
| Income Tax Expense | — | — | 117.0K | (14.1M) | 42.1M |
| Bottom Line | |||||
| Net Income | (204.7M) | (219.9M) | (167.4M) | (153.2M) | 111.2M |
| Earnings from Cont. Ops | (204.7M) | (219.9M) | (167.6M) | (155.1M) | 109.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (204.7M) | (219.9M) | (167.4M) | (153.2M) | 111.2M |
| Per Share | |||||
| Basic EPS | ($3.37) | ($3.72) | ($3.11) | ($3.69) | $2.46 |
| Diluted EPS | ($3.37) | ($3.72) | ($3.11) | ($3.69) | $2.38 |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 61.5M | 59.0M | 53.8M | 41.5M | 45.2M |
| Diluted Shares Outstanding | 61.5M | 59.0M | 53.8M | 41.5M | 46.6M |
| Profitability Metrics | |||||
| EBITDA | (208.4M) | (219.6M) | (167.2M) | (190.3M) | (132.0M) |
| D&A | 316.0K | 311.0K | 306.0K | 310.0K | 93.0K |
| EBIT | (208.7M) | (219.9M) | (167.5M) | (190.6M) | (132.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026